Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
The efficacy of DMDs is typically established via short clinical trials with a follow-up of 2-3 years, in highly select and motivated groups of MS patients. In clinical practice, DMDs are used for many years in a much more diverse patient population. Relatively little is known about the use of DMDs for MS in the population-based universal healthcare setting. The current study from Canada described the characteristics of a cohort of 10,418 MS patients exposed to their first DMD in the real-world setting; 74% were women [1].
At study entry, 17% of patients had some comorbidity (Charlson Comorbidity Index score ≥1). Mean age at first DMD was 39.6 years. Nearly 20% was aged ≥50 years when filling their first DMD and 3% was ≥60 years old. The mean age at first DMD prescription ranged from 35.9 years for alemtuzumab (n=37) to 43.6 years for teriflunomide (n=338).
Pattern of treatment changed over time, reflecting increased availability of DMDs. From 1996-2012, the most common first DMD prescriptions filled were for beta-interferon (72%) or glatiramer acetate (27%). From 2013-2018, the most common first DMD prescriptions filled were for glatiramer acetate (33%), dimethyl fumarate (27%), or beta-interferon (22%).
- Ng HS, et al. Characteristics of a population-based MS cohort treated with disease-modifying drugs. ECF 28th Annual Meeting. Abstract 06.
Posted on
Previous Article
« Real-world efficacy of ocrelizumab in MS patients Next Article
ECF 2020 Highlights Podcast »
« Real-world efficacy of ocrelizumab in MS patients Next Article
ECF 2020 Highlights Podcast »
Table of Contents: ECF 2020
Featured articles
ECF Round-Up Articles
No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS
Defining phenotypes of MS-related cognitive impairment
First long-term efficacy data of a BTK inhibitor
Novel disease-specific scale confirms huge impact of fatigue
Progressive aerobic exercise improves fatigue
Reliable and convenient method to assess cognitive function in MS patients
Tackling unmet MS-related cognitive challenges
Real-world efficacy of ocrelizumab in MS patients
Similar demographics, clinical characteristics, and treatment patterns in German claims study
Decreased EDSS after plasma exchange in NMOSD
No support for IVIG as treatment of acute attacks in NMOSD
Related Articles
November 25, 2020
No new safety signals in ofatumumab open-label data

November 8, 2021
Interictal pontine metabolism in migraine patients without aura
December 9, 2021
The importance of MS progression independent of relapses
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy